Celldex Therapeutics to Present at Inaugural Cancer Immunotherapy Conference

NEEDHAM, Mass.--(BUSINESS WIRE)-- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that the Company will be presenting at the Cancer Immunotherapy: A Long-Awaited Reality conference taking place on October 21, 2010, at the New York Academy of Medicine in New York.

Thomas Davis, M.D., Senior Vice President and Chief Medical Officer, will provide an overview of the Company’s Precision Targeted Immunotherapy Platform. Dr. Davis is scheduled to present at 1:45 pm EDT. Additionally, Tibor Keler, Ph.D., Senior Vice President and Chief Scientific Officer, will participate in a panel discussion titled “Autologous versus Allogeneic Immunotherapy” at 2:45 pm EDT.

There will be a corresponding live webcast of the conference, which can be accessed by visiting http://www.mdbpartners.com/vaccine.

Hosted by MD Becker Partners and BioBusiness.TV, the Cancer Immunotherapy: A Long-Awaited Reality conference includes keynote speakers, panelist and plenary sessions, company presentations, and intimate networking opportunities to meet the needs of all attendees. Pre-registration is required and attendance is limited to 150 individuals; no walk-ins. To register, or to obtain more information, please visit http://www.mdbpartners.com/vaccine or contact MD Becker Partners directly at [email protected].

About Celldex Therapeutics, Inc.

Celldex Therapeutics is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates. For more information, please visit http://www.celldextherapeutics.com.

About MD Becker Partners

MD Becker Partners is a boutique management and strategy consulting firm focusing on both public and private companies in the life sciences industry. The firm also works with venture capitalists, institutional investors, and others that provide capital to these companies. As a strategic advisor and partner, MD Becker Partners provides a full range of services to help its clients increase visibility, unlock stakeholder value, and access resources to grow their business. To accomplish this, the firm integrates relations, strategy, and operational capabilities and applies them to carefully conceived and expertly enacted tactics. For more information visit http://www.mdbpartners.com.

About BioBusiness.TV

BioBusiness.TV is the first independent Internet TV Network for Life Sciences Investors and Executives. The company creates video-based, industry focused business news and analysis programs. BioBusiness.TV produces and syndicates videos ranging from news and stock picks, to equity analyst insights, as well as C-level executive interviews on strategy, management, policy, marketing, science, and more. BioBusiness.TV’s latest Original Series, “The Stem Cell Review,” is a 10-part TV program on the science, medical applications, and business of stem cells, which provides a clear and concise understanding of the state of stem cells today, with the additional depth and expertise you would come to expect from the most renowned authorities in the field. For more information, visit http://www.biobusiness.tv.



CONTACT:

Celldex Therapeutics, Inc.
Anthony S. Marucci, 781-433-0771
President and CEO
or
Celldex Therapeutics, Inc.
Avery W. Catlin, 781-433-0771
Chief Financial Officer
[email protected]
or
For Media:
BMC Communications Group
Matthew Driscoll, 212-477-9007 x20
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical  Other Health  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.